Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

21. Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: putative implication of a low anti-carbamylated protein antibodies prevalence

Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: putative implication of a low anti-carbamylated protein antibodies prevalence 30233261 2018 11 14 1179-156X 10 2018 Open access rheumatology : research and reviews Open Access Rheumatol Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: putative implication of a low anti-carbamylated protein antibodies prevalence. 129-134 10.2147/OARRR.S163731 Anti-carbamylated protein antibodies (...) (anti-CarP Ab) represent a novel kind of autoantibodies specificity detectable in the sera of patients with rheumatoid arthritis (RA). They have been recently reported to be associated with increased mortality in Spanish patients with RA. The aim of our study was to compare the incidence mortality rates (IMRs) detected in RA patients from a tertiary Italian center with those reported in other European tertiary centers and to evaluate the putative role of anti-CarP Ab in modulating the low IMR

Open access rheumatology : research and reviews2018 Full Text: Link to full Text with Trip Pro

22. An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial

An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial 29745059 2018 08 24 2326-5205 2018 May 09 Arthritis & rheumatology (Hoboken, N.J.) An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From (...) a Pragmatic Open-Label Trial. 10.1002/art.40546 To evaluate, from a societal perspective, the incremental cost-effectiveness of withdrawing tumor necrosis factor inhibitor (TNFi) treatment compared to continuation of these drugs within a 1-year, randomized trial among rheumatoid arthritis patients with longstanding, stable disease activity or remission. Data were collected from a pragmatic, open-label trial. Cost-utility analysis was performed using the nonparametric bootstrapping method, and a cost

EvidenceUpdates2018

23. The Impact of Targeted Rheumatoid Arthritis Pharmacologic Treatment on Mental Health: A Systematic Review and Network Meta-Analysis

The Impact of Targeted Rheumatoid Arthritis Pharmacologic Treatment on Mental Health: A Systematic Review and Network Meta-Analysis 29873196 2018 08 29 2326-5205 70 9 2018 Sep Arthritis & rheumatology (Hoboken, N.J.) The Impact of Targeted Rheumatoid Arthritis Pharmacologic Treatment on Mental Health: A Systematic Review and Network Meta-Analysis. 1377-1391 10.1002/art.40565 Rheumatoid arthritis (RA) pharmacotherapy may impact mental health outcomes by improving pain and stiffness, potentially (...) NHS Foundation Trust, London, UK. Norton Sam S http://orcid.org/0000-0003-1714-9963 King's College London and King's College Hospital NHS Foundation Trust, London, UK. eng Journal Article Review 2018 07 31 United States Arthritis Rheumatol 101623795 2326-5191 2017 11 08 2018 05 15 2018 6 7 6 0 2018 6 7 6 0 2018 6 7 6 0 ppublish 29873196 10.1002/art.40565

EvidenceUpdates2018

24. Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis: A Nationwide Population-Based Cohort Study.

Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis: A Nationwide Population-Based Cohort Study. Background: Use of tumor necrosis factor inhibitors (TNFi) in patients with a history of cancer remains a clinical dilemma. Objective: To investigate whether TNFi treatment in rheumatoid arthritis (RA) is associated with increased risk for cancer recurrence. Design: Population-based cohort study based on linkage of nationwide registers. Setting

Annals of Internal Medicine2018

25. Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis

Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis 30127649 2018 11 14 1179-156X 10 2018 Open access rheumatology : research and reviews Open Access Rheumatol Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis. 103-111 10.2147/OARRR.S164738 This study aimed to: 1 (...) ) describe treatment patterns and drug utilization profile (in terms of therapeutic strategy used, switch, persistence and drug consumption variation) among adult patients affected by rheumatoid arthritis (RA), and 2) estimate the health care resource utilization and its associated direct cost for the management of RA patients. A retrospective cohort analysis, using administrative databases of six Local Health Units in Italy, was performed. All adult patients with a confirmed diagnosis of RA between

Open access rheumatology : research and reviews2018 Full Text: Link to full Text with Trip Pro

26. Is rheumatoid arthritis an innocent bystander in female reproductive problems? A comparative study of fertility in Nigerian women with and without rheumatoid arthritis

Is rheumatoid arthritis an innocent bystander in female reproductive problems? A comparative study of fertility in Nigerian women with and without rheumatoid arthritis 30185371 2018 11 14 2147-9720 5 3 2018 Sep European journal of rheumatology Eur J Rheumatol Is rheumatoid arthritis an innocent bystander in female reproductive problems? A comparative study of fertility in Nigerian women with and without rheumatoid arthritis. 179-183 10.5152/eurjrheum.2018.17180 Contrary to the old belief (...) that rheumatoid arthritis (RA) is rare in sub-Saharan Africa, recent reports have increasingly recognized that the burden of the disease has probably been long under-appreciated in West Africa. Thus, fertility and other attributes of the reproductive lives among women with RA have not received research attention in Africa. We aimed to compare the fertility between married Nigerian women with and without RA. A comparative study of 50 women with RA and 50 women without RA was conducted via the specialist

European journal of rheumatology2018 Full Text: Link to full Text with Trip Pro

27. Risk factor assessment of rheumatoid arthritis in North Kerala

Risk factor assessment of rheumatoid arthritis in North Kerala 30185372 2018 11 14 2147-9720 5 3 2018 Sep European journal of rheumatology Eur J Rheumatol Risk factor assessment of rheumatoid arthritis in North Kerala. 184-190 10.5152/eurjrheum.2018.17111 Rheumatoid arthritis (RA) is a multifactorial disease; it leads to disabling and painful chronic inflammatory arthritis. Its onset may be delayed or even prevented by modifying the risk factors involved. Many genetic, epigenetic (...) 10.5152/eurjrheum.2018.17111 PMC6116848 Ann Rheum Dis. 1990 Feb;49(2):76-80 2138449 N Engl J Med. 2007 Jul 19;357(3):266-81 17634462 J Clin Periodontol. 2008 Aug;35(8):668-73 18564145 Br J Rheumatol. 1998 Mar;37(3):274-81 9566667 Ann Rheum Dis. 2001 Mar;60(3):223-7 11171682 Nat Clin Pract Rheumatol. 2008 Mar;4(3):128-35 18253109 Ann Rheum Dis. 2010 Jan;69(1):54-60 19151010 Arthritis Rheum. 2004 Oct;50(10):3085-92 15476204 Arthritis Rheum. 2012 Nov;64(11):3553-63 22833339 Rheumatology (Oxford). 2015

European journal of rheumatology2018 Full Text: Link to full Text with Trip Pro

28. Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes 29934373 2018 07 07 1468-2060 2018 Jun 22 Annals of the rheumatic diseases Ann. Rheum. Dis. Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes. annrheumdis-2017-212830 10.1136/annrheumdis-2017-212830 To explore (...) associations between remission, based on clinical and ultrasound definitions, and future good radiographic and physical outcome in early rheumatoid arthritis (RA). Newly diagnosed patients with RA followed a treat-to-target strategy incorporating ultrasound information in the Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen (ARCTIC) trial. We defined 6-month remission according to Disease Activity Score, Disease

EvidenceUpdates2018

29. Rheumatoid arthritis

Rheumatoid arthritis Top results for rheumatoid arthritis - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top (...) search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for rheumatoid arthritis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic

Trip Latest and Greatest2018

30. Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis

Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how (...) human monoclonal antibody produced in Chinese Hamster Ovary cells. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear to slightly opalescent, colourless to slightly yellowish solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Rheumatoid arthritis Hyrimoz in combination with methotrexate, is indicated for: • the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease

European Medicines Agency - EPARs2018

31. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update July 2018 In partnership withComparative Effectiveness Review Number 211 Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov and Patient (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Donahue KE, Gartlehner G, Schulman ER, Jonas B, Coker-Schwimmer E, Patel SV, Weber RP, Lohr KN, Bann C, Viswanathan M. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update. Comparative Effectiveness Review No. 211. (Prepared by the RTI International–University of North Carolina

Effective Health Care Program (AHRQ)2018

32. Adalimumab (Hefiya) - Juvenile Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis

Adalimumab (Hefiya) - Juvenile Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 31 May 2018 EMA/CHMP/520007/2018 Committee for Medicinal (...) (PASI) score PBMC Peripheral blood mononuclear cells PC Process characterisation PD Pharmacodynamics PETG Polyethylene tetraphthalate copolymer PFS Pre-filled syringe Ph. Eur. European Pharmacopoeia PK Pharmacokinetics PP Process parameters PPS Per-protocol analysis set PPso Plaque Psoriasis PsA Psoriatic Arthritis PsO; Ps Psoriasis p.v. Paravenous PV Process validation R2 adj Adjusted correlation coefficient RA Rheumatoid Arthritis RGA Reporter Gene Assay s.c. subcutaneous SAE Serious adverse event

European Medicines Agency - EPARs2018

33. Adalimumab (Halimatoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis

Adalimumab (Halimatoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 31 May 2018 (...) of the Psoriasis Area and Severity Index (PASI) score PBMC Peripheral blood mononuclear cells PC Process characterisation PD Pharmacodynamics PETG Polyethylene tetraphthalate copolymer PFS Pre-filled syringe Ph. Eur. European Pharmacopoeia PK Pharmacokinetics PP Process parameters PPS Per-protocol analysis set PPso Plaque Psoriasis PsA Psoriatic Arthritis PsO; Ps Psoriasis p.v. Paravenous PV Process validation R2 adj Adjusted correlation coefficient RA Rheumatoid Arthritis RGA Reporter Gene Assay s.c

European Medicines Agency - EPARs2018

34. Exercise for rheumatoid arthritis of the hand.

Exercise for rheumatoid arthritis of the hand. BACKGROUND: Rheumatoid arthritis is an inflammatory polyarthritis that frequently affects the hands and wrists. Hand exercises are prescribed to improve mobility and strength, and thereby hand function. OBJECTIVES: To determine the benefits and harms of hand exercise in adults with rheumatoid arthritis. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library), MEDLINE, Embase, CINAHL, AMED

Cochrane2018

35. Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate 30013407 2018 11 14 1179-156X 10 2018 Open access rheumatology : research and reviews Open Access Rheumatol Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate. 97-101 10.2147/OARRR.S169152 The objective of this study was to assess the treatment for patients (...) with rheumatoid arthritis (RA) in the USA. This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). MTX is underused in the treatment of RA

Open access rheumatology : research and reviews2018 Full Text: Link to full Text with Trip Pro

36. Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink

Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink 29796636 2018 06 15 1462-0332 57 6 2018 06 01 Rheumatology (Oxford, England) Rheumatology (Oxford) Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink. 977-981 10.1093/rheumatology/key013 To examine temporal trends in all-cause and cause-specific mortality in RA. Data (...) of Medicine, University of Nottingham, Nottingham, UK. Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan. Mallen Christian C Arthritis Research UK Primary Care Centre, Keele University, Keele, UK. Zhang Weiya W Academic Rheumatology, Division of Rheumatology, Orthopaedics, and Dermatology, School of Medicine, University of Nottingham, Nottingham, UK. Grainge Matthew J MJ Division of Epidemiology and Public Health, School of Medicine, University of Nottingham

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

37. Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis

Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis 29884751 2018 07 13 1468-2060 77 8 2018 Aug Annals of the rheumatic diseases Ann. Rheum. Dis. Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis. 1099-1106 10.1136/annrheumdis-2017-212612 Recent advances in knowledge of the pathogenesis of rheumatoid (...) arthritis and/or unclassified arthritis and in patients with RA. We searched PubMed, EMBASE and Cochrane databases for English articles published from 2006 to 2016 using the keywords 'undifferentiated arthritis' or 'very early rheumatoid arthritis' with 'therapy' or 'treatment'. Main outcome was RA occurrence, defined as fulfilment of the 1987 ACR criteria. The MA was performed with RevMan with the Mantel-Haenszel method. Among 595 abstracts screened, 10 reports of trials were selected. The studies

EvidenceUpdates2018

38. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease

Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease 29764964 2018 05 16 0315-162X 2018 May 15 The Journal of rheumatology J. Rheumatol. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. jrheum.170926 10.3899/jrheum.170926 To evaluate the cardiovascular safety of abatacept (ABA) versus tumor necrosis (...) factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients with and without underlying cardiovascular disease (CVD). We identified RA patients with and without baseline CVD who initiated ABA or TNFi by using data from 2 large US insurance claims databases: Medicare (2008-2013) and Truven MarketScan (2006-2015). After stratifying by baseline CVD, ABA initiators were 1:1 propensity score (PS) matched to TNFi initiators to control for > 60 baseline covariates. Cox proportional hazards regression

EvidenceUpdates2018

39. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial

Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial 29575803 2018 06 15 2326-5205 2018 Mar 25 Arthritis & rheumatology (Hoboken, N.J.) Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial. 10.1002/art.40493 To evaluate whether tocilizumab (...) (TCZ) monotherapy is noninferior to treatment with TCZ plus methotrexate (MTX) for maintaining clinical responses in patients with rheumatoid arthritis (RA) in whom low disease activity is achieved with TCZ plus MTX. Patients with RA who experienced an inadequate response to MTX received MTX plus TCZ 162 mg subcutaneously. At 24 weeks, patients who achieved a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) of ≤3.2 were randomized to receive TCZ monotherapy

EvidenceUpdates2018

40. Rheumatoid arthritis

Rheumatoid arthritis Autosynthesis - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search

Trip Evidence Maps2018